For a patient with comorbid obesity, a history of recurrent genital infections, or at risk for ketoacidosis, a GLP-1 receptor agonist may be the preferred option, whereas for a patient with heart failure or significant albuminuria, the benefits of an SGLT2 inhibitor would outweigh these risks. Here, SLC5A2 is linked to heart failure.